SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Wanders I)
 

Sökning: WFRF:(Wanders I) > (2010-2014) > AdCD40L immunogene ...

  • Malmström, Per-UnoUppsala universitet,Urologkirurgi (författare)

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial

  • Artikel/kapitelEngelska2010

Förlag, utgivningsår, omfång ...

  • American Association for Cancer Research,2010
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-110921
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-110921URI
  • https://doi.org/10.1158/1078-0432.CCR-10-0385DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-125943URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PURPOSE: Immunotherapy with Bacillus Calmette-Guerin (BCG) instillation is recommended for high-risk, non-muscle invasive bladder cancer. Bacillus Calmette-Guerin is not effective in advanced tumors, and better alternatives are warranted. Immunostimulating gene therapy with adenoviral vectors expressing CD40 ligand (AdCD40L) has shown efficacy in tumor models. CD40 ligand stimulates systemic immunity and may be effective in local and invasive human disease.EXPERIMENTAL DESIGN: Patients with invasive bladder cancer scheduled for cystectomy or patients with T(a) tumors were enrolled in a phase I/IIa trial. Patients were treated with three cycles of intrabladder Clorpactin WCS-90 prewash, followed by AdCD40L instillation 1 week apart. Safety, gene transfer, immune effects, and antitumor responses were monitored.RESULTS: All eight recruited patients were treated as scheduled, and therapy was well tolerated. The main adverse effect was transient local pain during prewash. Postoperatively, urinary tract infections and one case of late septicemia with elevated potassium were reported. No adverse events were ascribed to vector therapy. Gene transfer was detected in biopsies, and bladders were heavily infiltrated with T cells. The effector marker IFN-gamma increased in biopsies, whereas levels of circulating T regulatory cells were reduced. Histologic evaluation indicated that AdCD40L therapy reduced the load of malignant cells.CONCLUSIONS: To our knowledge, this is the first report on immunogene therapy in bladder cancer and the first using AdCD40L in vivo. Local AdCD40L gene therapy was safe, boosted immune activation, and should be further evaluated as a single or an adjuvant therapy for urothelial malignancies.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Loskog, Angelica S. I.Uppsala universitet,Enheten för klinisk immunologi(Swepub:uu)angelosk (författare)
  • Lindqvist, Camilla A.Uppsala universitet,Enheten för klinisk immunologi (författare)
  • Mangsbo, Sara M.Uppsala universitet,Enheten för klinisk immunologi(Swepub:uu)saman132 (författare)
  • Fransson, MoaUppsala universitet,Enheten för klinisk immunologi(Swepub:uu)moafr634 (författare)
  • Wanders, AlkwinUppsala universitet,Institutionen för genetik och patologi,Wanders(Swepub:umu)alwa0025 (författare)
  • Gardmark, TrulsUppsala universitet,Urologkirurgi (författare)
  • Tötterman, Thomas H.Uppsala universitet,Enheten för klinisk immunologi(Swepub:uu)thomtott (författare)
  • Uppsala universitetUrologkirurgi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Clinical Cancer Research: American Association for Cancer Research16:12, s. 3279-32871078-04321557-3265

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy